Je veux savoir à propos de…

lotter on DSK11XQN23PROD with NOTICES1

35292

Federal Register / Vol. 86, No. 125 / Friday, July 2, 2021 / Notices
facilities covered by the EEOICPA
programs; or familiarity, experience, or history of participation with the EEOICPA program. Any interested person or organization may nominate one or more individuals for membership. Interested persons are also invited and encouraged to submit statements in support of nominees.
The ABRWH consists of not more than 20 members appointed by the President of the United States. As required by 42 U.S.C. 7384oa2, the President makes appointments to the ABRWH in consultation with organizations with expertise on worker health issues in order to ensure that the membership of the ABRWH reflects a balance of scientific, medical, and worker perspectives. As required by 42
U.S.C. 7384oa3, the President designates a Chair for the ABRWH from among its members. The authorizing statutory provision under 42 U.S.C.
7384o and Section 4 of Executive Order 13179 do not include a limit for terms of appointment for ABRWH members.
Nomination Process: Any interested person or organization may nominate one or more qualified individuals for membership. If you would like to nominate an individual or yourself for appointment to the ABRWH, please submit the following information:
The nominees contact information name, title, business address, business phone, fax number, and/or business email address and current employment or position.
A copy of the nominees resume or curriculum vitae; category of membership e.g., scientific, medical, and/or worker perspective that the nominee represents; a summary of the background, experience, and qualifications that addresses the nominees suitability for the nominated membership category identified above.
Articles or other documents the nominee has authored that indicate the nominees knowledge, experience, and expertise in the fields of health physics, industrial hygiene, toxicology, epidemiology, occupational medicine, or the worker perspective in the nuclear facilities covered by the EEOICPA
program; or familiarity, experience, or history of participation with the EEOICPA program. Nominations may be submitted by the candidate him or herself, or by the person/organization recommending the candidate.
At least one letter of recommendation from persons not employed by the U.S. Department of Health and Human Services. Candidates may submit letters from current HHS
employees if they wish, but at least one letter must be submitted by a person not
VerDate Sep<11>2014

17:12 Jul 01, 2021

Jkt 253001

employed by an HHS agency e.g., CDC, NIH, FDA, etc..
The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.
FR Doc. 202114204 Filed 7121; 8:45 am BILLING CODE 416318P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and Prevention 30Day210307

Agency Forms Undergoing Paperwork Reduction Act Review In accordance with the Paperwork Reduction Act of 1995, the Centers for Disease Control and Prevention CDC
has submitted the information collection request titled Gonococcal Isolate Surveillance Project GISP to the Office of Management and Budget OMB for review and approval. CDC
previously published a Proposed Data Collection Submitted for Public Comment and Recommendations notice on March 8, 2021 to obtain comments from the public and affected agencies. CDC did not receive comments related to the previous notice. This notice serves to allow an additional 30
days for public and affected agency comments.
CDC will accept all comments for this proposed information collection project.
The Office of Management and Budget is particularly interested in comments that:
a Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
b Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
c Enhance the quality, utility, and clarity of the information to be collected;

PO 00000

Frm 00034

Fmt 4703

Sfmt 4703

d Minimize the burden of the collection of information on those who are to respond, including, through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and e Assess information collection costs.
To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call 404 6397570.
Comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular information collection by selecting Currently under 30-day ReviewOpen for Public Comments or by using the search function. Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to 202 3955806. Provide written comments within 30 days of notice publication.
Proposed Project Gonococcal Isolate Surveillance ProjectRevisionNational Center for HIV/AIDS, Viral Hepatitis, STD, TB
Prevention NCHHSTP, Centers for Disease Control and Prevention CDC.
Background and Brief Description The Gonococcal Isolate Surveillance Project GISP was created in 1986 to monitor trends in antimicrobial susceptibilities of Neisseria gonorrhoeae strains in the United States. GISP
continues to be a collaboration between different branches of the CDCs Division of STD Prevention, selected regional laboratories, and selected state/local public health departments and their associated STD specialty care clinics in the United States. National organizations, local jurisdictions and individuals use data collected in GISP
to understand, monitor, and prevent further transmission of antibiotic resistant strains of N. gonorrhoeae. Data from GISP are used to establish a scientific basis for the selection of gonococcal therapies and to allow proactive changes to treatment guidelines before widespread resistance and failures of treatment occur. To increase capacity to detect and monitor resistant gonorrhea and to improve the specificity of GISP, this revision is being submitted to include collection of remnant nucleic acid amplification test NAAT

E:FRFM02JYN1.SGM

02JYN1